Fran Boyle
speaker
110 appearances
2 recordings
1 series
first heard Nov 2016
last heard Jun 2018
Fran Boyle’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
And additional genes are looked at, which are not the inherited breast cancer genes, so not the ones that tell you whether you got it from your granny and your auntie, but the ones that are actually mutated in the cancer that are associated with growth and spread.
And the test can come back with more or less three kinds of answers.
One, low risk, don't worry about it.
I'm going to
That's right.
Number two can come back with, yes, up to a 30% risk of recurrence and spread.
So we call that a high risk.
And then there's the sort of fuzzy zone in the middle of the intermediate risk.
And that's the group of people who were involved in this clinical trial called the Taylor X trial.
That's right.
So those are people with a very hormonal cancer, not growing quickly.
Hormone-blocking treatment should be enough to keep them safe.
So what they found in the mid-range was that modern chemotherapy of the sort that we would give here did not have an extra benefit over modern hormone-blocking treatment.
So most of the women... So this is
Younger women, tamoxifen.
Older women, what we call aromatase inhibitors, so some of the newer hormone-blocking drugs.
And these women were doing actually well without chemotherapy.
And the half of the group who got chemotherapy actually weren't doing any better.
And they were, of course, having more side effects.
So in that circumstance, it would be a very good thing not to offer them chemotherapy.
Showing 21–40 of 110 · page 2 of 6
← Previous
Next →